Last updated: 11/03/2018 17:43:56
A Meta-Analysis of the Cummulative Incidence of Hypertension for Pazopanib Across Three RCC Studies: VEG102616. VEG105192, and VEG107769
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Trial overview
Official title: A Meta-Analysis of the Cumulative Incidence of Hypertension in the first Month of Treatment with Pazopanib Across Three Renal Cell Carcinoma Studies: VEG102616, VEG105192, and VEG107769
Trial description: The objective of this analysis is to understand the pattern of the first occurrence of hypertension in renal cell carcinoma studies. Data from three studies were analysed: VEG102616, VEG105192, and VEG107769. The cumulative incidence of hypertension by day 9, day 22 and day 29 was summarized by frequency and percentage. Three clinically relevant cutoffs were used to define hypertension. These cutoffs have been included in NCI CTC version 3 (150/100 mmHg) and version 4 (140/90 mmHg and 160/100 mmHg).
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Cumulative incidence of hypertension
Timeframe: day 9, 22, and 29
Secondary outcomes:
Not applicable
Interventions:
Other: N/A
Enrollment:
586
Observational study model:
Other
Primary completion date:
Not applicable
Time perspective:
Retrospective
Clinical publications:
Not applicable
Medical condition
Carcinoma, Renal Cell
Product
pazopanib
Collaborators
Not applicable
Study date(s)
May 2010 to May 2010
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
none
- Studies included in the meta-analysis include VEG102616, VEG105192, and VEG107769
Inclusion and exclusion criteria
Inclusion criteria:
- Studies included in the meta-analysis include VEG102616, VEG105192, and VEG107769
Trial location(s)
No location data available.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Finalized
Actual primary completion date
Not applicable
Actual study completion date
2010-24-05
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website